Skip to main content
. 2016 Jun 20;9:3661–3669. doi: 10.2147/OTT.S96427

Figure 2.

Figure 2

Comparison of the complete remission rate in refractory AML (A) and middle-and-high-risk MDS (B) patients administered new and conventional priming regimens.

Abbreviations: CR, complete remission; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.